Cellectar Biosciences Files 8-K
Ticker: CLRB · Form: 8-K · Filed: Nov 1, 2024 · CIK: 1279704
| Field | Detail |
|---|---|
| Company | Cellectar Biosciences, Inc. (CLRB) |
| Form Type | 8-K |
| Filed Date | Nov 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
Cellectar filed an 8-K on Nov 1st, reporting events and financials. Details TBD.
AI Summary
Cellectar Biosciences, Inc. filed an 8-K on November 1, 2024, reporting other events and financial statements. The company, incorporated in Delaware, has its principal executive offices in Florham Park, NJ. This filing does not contain specific financial figures or details about the 'other events' reported.
Why It Matters
This 8-K filing indicates that Cellectar Biosciences has reported significant events and financial statements to the SEC, which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain specific material information that would immediately alter risk assessment.
Key Players & Entities
- Cellectar Biosciences, Inc. (company) — Registrant
- November 1, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Florham Park, NJ (location) — Address of principal executive offices
- 100 Campus Drive (address) — Principal executive office street address
FAQ
What specific 'Other Events' are being reported by Cellectar Biosciences in this 8-K filing?
The provided text for the 8-K filing indicates 'Other Events' as an item information, but does not specify the nature of these events.
What is the significance of the 'Financial Statements and Exhibits' being filed?
The filing lists 'Financial Statements and Exhibits' as an item information, suggesting that updated financial data or related documents are being provided to the SEC.
When was Cellectar Biosciences, Inc. incorporated?
Cellectar Biosciences, Inc. was incorporated in Delaware.
What is the primary business address for Cellectar Biosciences, Inc.?
The primary business address for Cellectar Biosciences, Inc. is 100 Campus Drive, Florham Park, NJ, 07932.
What is the Commission File Number for Cellectar Biosciences, Inc.?
The Commission File Number for Cellectar Biosciences, Inc. is 1-36598.
Filing Stats: 454 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-11-01 17:15:33
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB The Nasdaq Capital M
Filing Documents
- tm2427349d1_8k.htm (8-K) — 26KB
- tm2427349d1_ex99-1.htm (EX-99.1 CHARTER) — 8KB
- tm2427349d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-113549.txt ( ) — 209KB
- clrb-20241101.xsd (EX-101.SCH) — 3KB
- clrb-20241101_lab.xml (EX-101.LAB) — 33KB
- clrb-20241101_pre.xml (EX-101.PRE) — 22KB
- tm2427349d1_8k_htm.xml (XML) — 3KB
01
Item 8.01. Other Events . On November 1, 2024, the Company issued a press release announcing that it had received a letter from Nasdaq, Inc. informing the Company that it had regained compliance with Nasdaq Listing Rule 5250(c)(1). A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Number Title 99.1 Press release dated November 1, 2024, titled "Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q" 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. Date: November 1, 2024 By: /s/ Chad J. Kolean Name: Chad J. Kolean Title: Chief Financial Officer